CyDex Pharmaceuticals Inc., a Lenexa, Kansas-based developer of drugs that “address limitations of current therapies in selected established,” has filed for a $50 million IPO. It plans to trade on the Nasdaq under ticker symbol CYDX, with Pacific Growth Equities serving as lead underwriter.
CyDex has raised over $29 million in VC funding since 2000, from firms like TVM Capital, RiverVest Venture Partners, Life Sciences Opportunities Funds, S.R. One Ltd. and Eastman Chemical Company Investments. www.cydexinc.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.